"RAD-140 is a potent oral SARM that produces robust anabolic activity in muscle and bone while minimizing activity in reproductive tissues in animal models." — Narayanan et al., Endocrine-Related Cancer Its appeal lies in the claim that it delivers steroid-like results without the same level of androgenic risk. It was originally developed by Radius Health as a potential treatment for muscle wasting, osteoporosis, and hormone-sensitive breast cancer.
→ In preclinical studies, RAD-140 has shown neuroprotective effects, reducing brain cell death from amyloid toxicity — the type implicated in Alzheimer’s disease.→ While far from proven in humans, this raises interest in its potential beyond muscle. → By strongly activating androgen receptors in muscle tissue, RAD-140 may improve neuromuscular efficiency, translating to heavier lifts and better training performance.→ This makes it attractive to both strength athletes and physique competitors. Originally developed as a potential treatment for muscle wasting diseases, osteoporosis, and certain types of breast cancer, RAD-140 has since gained attention outside the lab as a so-called "safer alternative to steroids." For advanced athletes, stacking RAD‑140 and LGD‑4033 can create a hybrid protocol — combining RAD‑140’s potent anabolic activity with LGD‑4033’s steady lean mass preservation — but this approach requires bloodwork monitoring and proper PCT to ensure safety In a Phase I clinical trial, reported that LGD‑4033 temporarily reduced testosterone and sex hormone-binding globulin (SHBG) levels in a dose-dependent manner, though levels normalized within weeks post-cycle.
It has a high anabolic to androgenic ratio, making it effective for building muscle mass and strength while minimizing androgenic side effects. RAD-140 improves muscle mass and strength by selectively binding to androgen receptors in muscle and bone tissues, stimulating anabolic activity without affecting other organs. At first glance, RAD-140 appears to be a modern alternative to testosterone — a compound designed to deliver anabolic benefits without the systemic side effects of traditional steroids. Early preclinical studies suggested that RAD-140 could promote lean muscle growth and bone strength without converting into estrogen or dihydrotestosterone (DHT) — two pathways responsible for many testosterone-related side effects. Outside of medical use, testosterone has a long history in bodybuilding and athletic performance as the foundational anabolic steroid for muscle mass and strength gains. RAD-140, on the other hand, is an experimental SARM designed to selectively target muscle and bone tissue, with the promise of building lean muscle without the systemic effects of traditional steroids.
According to a study by Jayaraman and colleagues, the decline in testosterone levels in men during normal aging increases the risk of dysfunction and disease in androgen-responsive tissues, including the brain. RAD-140 has also displayed a dramatic increase in muscle tissue, muscle mass, and cardioprotective effects via lowering blood lipids LDL, HDL, and triglycerides in clinical research. Development of selective androgen receptor modulators (SARMs). It's crucial to start with a lower dose and gradually increase it to assess tolerance and minimize potential side effects.
Additionally, RAD-140 can help reduce body fat while preserving lean muscle tissue. RAD-140 users often report increased muscle mass, improved strength, enhanced endurance, and faster recovery times. In preclinical studies, RAD-140 demonstrates a significant increase in lean body mass and muscle hypertrophy.

Gender: Female

Social links